These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26503641)

  • 1. A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
    Suhasini AN; Wang L; Holder KN; Lin AP; Bhatnagar H; Kim SW; Moritz AW; Aguiar RCT
    Leukemia; 2016 Mar; 30(3):617-626. PubMed ID: 26503641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
    Smith PG; Wang F; Wilkinson KN; Savage KJ; Klein U; Neuberg DS; Bollag G; Shipp MA; Aguiar RC
    Blood; 2005 Jan; 105(1):308-16. PubMed ID: 15331441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.
    Kim DU; Kwak B; Kim SW
    Biochem Biophys Res Commun; 2019 Jan; 508(3):825-831. PubMed ID: 30528730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival.
    Nam J; Kim DU; Kim E; Kwak B; Ko MJ; Oh AY; Park BJ; Kim YW; Kim A; Sun H; Jung Y; Lee JH; Shin HJ; Park I; Song DK; Jeong JY; Lee YH; Kim SW
    Leukemia; 2019 Dec; 33(12):2912-2923. PubMed ID: 31138843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1α intersect to regulate angiogenesis in B-cell lymphoma.
    Ethiraj P; Sasi B; Holder KN; Lin AP; Qiu Z; Jaafar C; Elkhalili A; Desai P; Saksena A; Ritter JP; Aguiar RCT
    Br J Haematol; 2022 Jul; 198(2):349-359. PubMed ID: 35411936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.
    Kim SW; Rai D; Aguiar RC
    Clin Cancer Res; 2011 Nov; 17(21):6723-32. PubMed ID: 21742807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
    Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
    [No Abstract]   [Full Text] [Related]  

  • 8. Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL.
    Kim SW; Rai D; McKeller MR; Aguiar RC
    Blood; 2009 Jun; 113(24):6153-60. PubMed ID: 19369227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
    Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
    Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.
    Sasi B; Ethiraj P; Myers J; Lin AP; Jiang S; Qiu Z; Holder KN; Aguiar RCT
    Leukemia; 2021 Jul; 35(7):1990-2001. PubMed ID: 33299141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
    Lehrke M; Kahles F; Makowska A; Tilstam PV; Diebold S; Marx J; Stöhr R; Hess K; Endorf EB; Bruemmer D; Marx N; Findeisen HM
    J Mol Cell Cardiol; 2015 Apr; 81():23-33. PubMed ID: 25640159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
    Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
    PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma.
    Kim J; Jeong D; Nam J; Aung TN; Gim JA; Park KU; Kim SW
    Gene; 2015 Mar; 558(1):173-80. PubMed ID: 25576220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.
    Susuki-Miyata S; Miyata M; Lee BC; Xu H; Kai H; Yan C; Li JD
    Proc Natl Acad Sci U S A; 2015 Apr; 112(14):E1800-9. PubMed ID: 25831493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis.
    Joshi S; Singh AR; Zulcic M; Durden DL
    Mol Cancer Res; 2014 Oct; 12(10):1520-31. PubMed ID: 25103499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.
    Cooney JD; Aguiar RC
    Blood; 2016 Dec; 128(25):2886-2890. PubMed ID: 27756749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roflumilast treatment inhibits lung carcinogenesis in benzo(a)pyrene-induced murine lung cancer model.
    Yeo CD; Kim YA; Lee HY; Kim JW; Kim SJ; Lee SH; Kim YK
    Eur J Pharmacol; 2017 Oct; 812():189-195. PubMed ID: 28684234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
    Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
    Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.
    Kelly K; Mejia A; Suhasini AN; Lin AP; Kuhn J; Karnad AB; Weitman S; Aguiar RC
    Clin Cancer Res; 2017 Mar; 23(5):1186-1192. PubMed ID: 27542768
    [No Abstract]   [Full Text] [Related]  

  • 20. PI3K/AKT and Mdm2 activation are associated with inhibitory effect of cAMP increasing agents on DNA damage-induced cell death in human pre-B NALM-6 cells.
    Ghorbani A; Jeddi-Tehrani M; Saidpour A; Safa M; Bayat AA; Zand H
    Arch Biochem Biophys; 2015 Jan; 566():58-66. PubMed ID: 25524737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.